ÂÜÀòÂÒÂ×

Mathias Hukkelhoven, Ph.D., joined LianBio as R&D Strategy Advisor in September 2021 after retiring from Bristol Myers Squibb. At BMS after the acquisition of Celgene in 2019 he was Sr.VP and responsible for their global Regulatory Sciences and Safety organization. Before the acquisition between 2010 and 2019, he was responsible for a large part of the Global Development organization in BMS including Regulatory, Safety, Biostatistics, Clinical Pharmacology, and R&D China. Under Math’s responsibility for the China R&D group, BMS received the first-ever PD-1 approval in China (for nivolumab) and the first-ever approval for an oral Hepatitis C regimen (daclatasvir plus asunaprevir).

Prior to joining BMS in 2010, he was at Novartis for 17 years and held increasingly important positions including Head of US Regulatory Affairs and from 2002 onwards Sr. VP, Head of Global Regulatory Affairs. Prior to moving to the US in 1994 Math worked at Hoffmann La Roche in Switzerland as Group Leader in Global Regulatory Affairs. He first joined the pharmaceutical industry in 1984 with Organon in the Netherlands, following a role as Research Fellow of the Dutch Cancer Society with the University of Nijmegen, The Netherlands. Math has a wealth of experience in global regulatory affairs and drug development, evidenced by his contribution to more than 50 NCEs and hundreds of new indications/formulations over his career to date. He was a member of all senior R&D governance Boards at Novartis and BMS.

Math has participated in activities that have shaped health authority interactions for the industry, including serving as chairman of the Regulatory Affairs Coordinating Committee at PhRMA, and recently as a PhRMA negotiator for the PDUFA VII negotiations with FDA. He is widely regarded as one of the most experienced global regulatory leaders in the industry.

Math received his B.S. and Ph.D. honors degrees in Biology and Biochemistry from the University of Nijmegen, the Netherlands.